Spyre Therapeutics (SYRE) Operating Income (2016 - 2025)
Historic Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$56.9 million.
- Spyre Therapeutics' Operating Income fell 270.08% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 1056.58%. This contributed to the annual value of -$208.6 million for FY2024, which is 1392.35% up from last year.
- Per Spyre Therapeutics' latest filing, its Operating Income stood at -$56.9 million for Q3 2025, which was down 270.08% from -$41.9 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Operating Income registered a high of -$6.7 million during Q2 2021, and its lowest value of -$159.2 million during Q2 2023.
- Its 5-year average for Operating Income is -$39.7 million, with a median of -$24.4 million in 2022.
- In the last 5 years, Spyre Therapeutics' Operating Income crashed by 61019.04% in 2023 and then skyrocketed by 7227.75% in 2024.
- Over the past 5 years, Spyre Therapeutics' Operating Income (Quarter) stood at -$20.4 million in 2021, then grew by 6.26% to -$19.2 million in 2022, then crashed by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then grew by 7.13% to -$56.9 million in 2025.
- Its Operating Income was -$56.9 million in Q3 2025, compared to -$41.9 million in Q2 2025 and -$53.6 million in Q1 2025.